Successful treatment of hard flaccid syndrome with multimodal therapy: a case report study (2024)

Hard Flaccid Syndrome (HFS) can be a disease management challenge due to its complex nature and the lack of a standardized treatment regimen [1]. The current approach to managing HFS involves a multifaceted strategy integrating medical, physical, and psychological interventions to overcome the various symptoms associated with the condition [2, 3]. While pharmaceutical solutions are limited, available medications can relieve pain and improve erectile function [2, 4]. In addition, physical therapy, especially for the pelvic floor, has shown potential in relieving symptoms [1]. This is supported by some case reports where patients have experienced notable improvement, especially in cases involving prolonged penile pain [2].

Recognizing the gaps in the literature and the lack of large-scale clinical trials is crucial. Reliance on anecdotal evidence and case reports in HFS highlights the need for more comprehensive research and standardized reporting [2]. Doing so will help determine the effectiveness of existing interventions and lay the foundation for innovative treatment modalities. A recent survey underscores the importance of developing multimodal and personalized treatment strategies for HFS patients, given the prevailing lack of familiarity among professionals, the necessity for ongoing education and research to enhance diagnostic accuracy, and the imperative to improve patient care through effective treatment strategies [5].

This case report strives to enhance the existing knowledge, offer valuable insights, and foster a deeper comprehension of HFS. Its ultimate goal is to contribute to developing more effective and targeted interventions for this perplexing condition.

Based on previous literature, diagnostic tests for HFS, such as blood profile, penile Doppler, and imaging methods, usually yield normal results. Diagnosis largely depends on the patient’s medical history. Anamnesis plays the most important role in making a diagnosis [2].

When making a differential diagnosis for HFS, it is essential to exclude conditions such as pelvic floor dysfunction, Peyronie’s disease, psychogenic erectile dysfunction, chronic prostatitis/chronic pelvic pain syndrome, neurological and vascular disorders, as well as potential hormonal imbalances, and past penile trauma or infections. Accurate diagnosis requires careful consideration of these conditions through detailed history taking, physical examination, and specific diagnostic tests, including hormone profile and imaging studies.

The lack of studies on HFS makes urologists inexperienced in its prognosis and management [5].

HFS is a multifaceted urological condition that remains elusive in its etiology and clinical management [1]. A complex interaction of biological, psychological, and social factors is hypothesized, with stress often playing a pivotal role [3]. The resultant psychosexual implications of HFS can be devastating, leading to physical discomfort and significant psychological distress, including anxiety, depression, and altered self-perception [1, 4, 6].

Historically, management strategies for HFS have leaned towards pain management, stress reduction, and physical therapies [1]. However, given the need for consistent efficacy and the absence of a standardized therapeutic approach, there is a pressing need for innovative treatment modalities [2]. While shock wave therapy has shown promise in various chronic pain conditions, its application to HFS is still nascent but potentially promising [7, 8].

LiSWT provides a non-invasive method to induce mechanical stress and microtrauma in targeted tissues [9]. This, in turn, can lead to a series of biological reactions, notably neovascularization by angiogenic factors [7]. The cascading effect of angiogenic factors released due to the therapy might improve blood supply and alleviate some of the symptoms of HFS [10,11,12] (Fig.1).

In the presented case, a patient with a clear manifestation of HFS showed remarkable improvement after undergoing a multimodal regimen of daily tadalafil 5 mg, 6 sessions of LiSWT, and LiSWT. The decision to combine these treatments is underpinned by the belief that the pathophysiology of HFS might overlap with that of ED [1, 12]. Thus, strategies effective against ED might benefit HFS patients. Breakdown of cyclic nucleotides: cAMP and cGMP is accomplished by the enzymes PDE5-Is [13]. PDE5-I increases nitric oxide (NO) present after sexual stimulation [14]. After NO is released, inhibition of PDE5 leads to the accumulation of cGMP levels, playing a role in the relaxation of smooth muscles and the influx of blood for penile erection [14]. Concomitant treatment with PDE5-I can help improve ED, which is often present in men with HFS. Given the complex symptom cluster seen with HFS, single-modality treatment may not be successful. Multi-modal therapy with LiSWT, PDE5-I, pelvic floor therapy, and/or behavioral health interventions are likely to be the most effective treatment strategy [13].

In a recent article, a patient who presented to the clinic with complaints related to HFS was found to have an annular tear with L5-S1 disc herniation [15]. This suggested that it may be related to pathologic activation of the pelvic/pudendal hypogastric reflex and strengthened the hypothesis that it produces symptoms according to the affected anatomical area [15]. HFS occurring after trauma (sexual intercourse, masturbation) while the penis is erect indicates end organ pathology for stimulating sympathetic activity excessively. We think that we benefited from our treatment by downregulating sympathetic triggers. However, according to this etiological theory, LiSWT may be useless in diseases that may trigger this excessive sympathetic activity at another level - at the level of the pudendal nerve or cauda equina - such as blunt perineal trauma, sacral radiculopathy.

While this case provides a promising trimodal therapy, it is essential to note that the results represent only one individual’s response. A larger sample size and randomized clinical trials will be essential to validate the therapy’s benefits and potential drawbacks.

In conclusion, while HFS remains a challenging condition in men’s health, applying physical therapy and LiSWT combined with daily 5 mg PDE5-I offers a reassuring, effective treatment.

Author notes

1. These authors contributed equally: R. Omer Yazar, Muhammed A. M. Hammad.

Authors and Affiliations

1. Bagcilar Research and Training Hospital, Istanbul, Turkey

   R. Omer Yazar

2. Department of Urology, University of California, Irvine, CA, USA

   Muhammed A. M. Hammad,David W. Barham,Babak Azad&Faysal A. Yafi

Contributions

ROY & MAMH conceptualized the study, retrieved, and analyzed the data, and wrote/edited the manuscript. DWB conceptualized the study, wrote/edited the manuscript. BA wrote/ edited the manuscript. FAY contributed to project conception/design and manuscript writing/editing. All authors read and approved the final manuscript

Corresponding author

Correspondence to Muhammed A. M. Hammad.

Competing interests

ROY, MAMH, DWB, BA: none; FAY: Coloplast: Advisory board, speaker; Endo: Advisory board; Haleon: Advisory board; Halozyme: Advisory board, speaker; Masimo: Intellectual property; Softwave: Advisory board; Sprout: Consultant; Vertica: Research investigator; Xialla: Advisory board.

Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/.

Reprints and permissions